Raija Silvennoinen

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

Journal: iScience

Published: February 23, 2026

A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.

A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.

Journal: Annals of hematology

Published: September 20, 2024

Correction to: Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.

Correction to: Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.

Journal: Annals of hematology

Published: September 13, 2024

Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.

Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.

Journal: Annals of hematology

Published: February 27, 2024

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Journal: Cancers

Published: January 27, 2024

Large differencies in age-specific survival in multiple myeloma in the nordic countries.

Large differencies in age-specific survival in multiple myeloma in the nordic countries.

Journal: Blood cancer journal

Published: December 20, 2023

Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland.

Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland.

Journal: Future oncology (London, England)

Published: October 13, 2023

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy.

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy.

Journal: Cancers

Published: March 28, 2023

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.

Journal: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Published: December 31, 2022

A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families.

A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families.

Journal: EJHaem

Published: July 22, 2022

Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.

Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study.

Journal: Journal of clinical apheresis

Published: July 08, 2022

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.

Journal: European journal of haematology

Published: February 27, 2022

Showing 1-12 of 37

Last Updated: 09/26/2026